NeoPharm Announces FDA Grant of Orphan Drug Designation for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis

LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

MORE ON THIS TOPIC